Who Owns Rani Therapeutics Stock?
NASDAQ: RANIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 46.80%
- Held by insiders
- 4.91%
- Institutional holders
- 85
- Institutions 46.8%
- Insiders 4.9%
- Public and other 48.3%
Who owns Rani Therapeutics stock?
Institutional investors own about 46.8% of Rani Therapeutics's shares, spread across 85 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 4.91% of RANI.
The largest institutional holders are Samsara BioCapital, LLC (8.98%), RA Capital Management, L.P. (7.36%) and AWM Investment Company, Inc. (6.50%). Together, the top 10 institutions control 37.3% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their RANI positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of RANI
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Samsara BioCapital, LLC | 10.37M | 8.98% | +22.0% |
| RA Capital Management, L.P. | 8.50M | 7.36% | 0.0% |
| AWM Investment Company, Inc. | 7.50M | 6.50% | +15.4% |
| Vanguard Capital Management LLC | 4.56M | 3.95% | -1.3% |
| SymBiosis Capital Partners, LLC | 3.67M | 3.18% | -41.8% |
| Longaeva Partners L.P. | 2.33M | 2.02% | 0.0% |
| Polar Asset Management Partners Inc. | 2.32M | 2.01% | +100.0% |
| Siren, L.L.C. | 2.00M | 1.73% | 0.0% |
| Heights Capital Management, Inc | 934.58K | 0.81% | +100.0% |
| Geode Capital Management, LLC | 890.62K | 0.77% | -1.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of RANI
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.65M | 3.16% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 834.89K | 0.72% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 405.80K | 0.35% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 138.18K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 115.38K | 0.10% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 71.32K | 0.06% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 49.89K | 0.04% |
| VANGUARD Inst. INDEX Fd.S-Vanguard Inst. Total Stock Market Index Fd. | 31.50K | 0.03% |
| Invesco Exchange-Traded Fund Trust II-Invesco Nasdaq Biotechnology ETF | 6.97K | 0.01% |
| ProShares Trust-ProShares Ultra Nasdaq Biotechnology | 4.02K | 0.00% |
Frequently asked questions
Who is the largest shareholder of Rani Therapeutics?
Samsara BioCapital, LLC is the largest institutional shareholder of RANI, owning 8.98% of shares outstanding (10.37M shares) as of its latest 13F filing.
What percentage of Rani Therapeutics is owned by institutions?
Institutions own about 46.8% of RANI shares and 49.2% of the public float.
How much of Rani Therapeutics do insiders own?
Insiders, such as officers and directors, own about 4.91% of RANI shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.